[
  {
    "ts": null,
    "headline": "This 3 Stock Portfolio Provides Monthly Income",
    "summary": "If investors select their dividend-paying stocks in a structured manner, they can create a portfolio that provides monthly paydays.",
    "url": "https://finnhub.io/api/news?id=d21b81cfbb40bba0192115e7ec785908e230bd7cd1be5c4a4ff5f820741ebcd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757379180,
      "headline": "This 3 Stock Portfolio Provides Monthly Income",
      "id": 136674212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If investors select their dividend-paying stocks in a structured manner, they can create a portfolio that provides monthly paydays.",
      "url": "https://finnhub.io/api/news?id=d21b81cfbb40bba0192115e7ec785908e230bd7cd1be5c4a4ff5f820741ebcd4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Dips While Market Gains: Key Facts",
    "summary": "AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=db9d01d58ea6f51611fbf0b1afdf7cc62102ecc527ae9db07f00c0909a7a8b63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757374389,
      "headline": "AbbVie (ABBV) Stock Dips While Market Gains: Key Facts",
      "id": 136701665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=db9d01d58ea6f51611fbf0b1afdf7cc62102ecc527ae9db07f00c0909a7a8b63"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=8ab56ae38840c042b95bc01ec1c53d3428e4bf01991b386db3fba893772473d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757349060,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 136751572,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=8ab56ae38840c042b95bc01ec1c53d3428e4bf01991b386db3fba893772473d7"
    }
  },
  {
    "ts": null,
    "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
    "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
    "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757342520,
      "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
      "id": 136674206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
      "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411"
    }
  },
  {
    "ts": null,
    "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
    "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
    "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757340900,
      "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
      "id": 136674234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
      "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
    "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
    "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324865,
      "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
      "id": 136668842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227488268/image_1227488268.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
      "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason Every Investor Should Know About AbbVie (ABBV)",
    "summary": "This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors.",
    "url": "https://finnhub.io/api/news?id=40f9e357cde2602f1842c89d70e4541e2232c28dac060cb9ec223040aa3aae59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757320980,
      "headline": "1 Reason Every Investor Should Know About AbbVie (ABBV)",
      "id": 136669125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors.",
      "url": "https://finnhub.io/api/news?id=40f9e357cde2602f1842c89d70e4541e2232c28dac060cb9ec223040aa3aae59"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
    "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
    "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757316643,
      "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
      "id": 136668317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196154167/image_2196154167.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
      "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4"
    }
  }
]